Lenalidomidă Alkaloid-Int (Lenalidomide)

Lenalidomide exerts its effect by binding to the cereblon component of the CRL4‑E3 ubiquitin ligase complex. This binding changes the complex’s substrate preference, leading to the ubiquitination and subsequent proteasomal degradation of transcription factors Ikaros and Aiolos. The loss of these factors suppresses malignant plasma‑cell growth, enhances immune‑cell activity, and inhibits new blood‑vessel formation within the bone marrow.

The dose of Lenalidomidă Alkaloid-Int is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, renal function, and concomitant therapies. No universal dosing regimen can be provided here; the treating physician will calculate the appropriate amount and schedule according to current clinical guidelines and the patient’s overall health status.

Lenalidomidă Alkaloid-Int is classified as contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential should use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended, as the drug may be excreted in milk and affect the infant. Consultation with a healthcare professional is essential before any decision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lenalidomidă Alkaloid-Int. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After validation, the sales team will provide pricing, availability, shipping details (including any temperature‑controlled requirements) and assist with import documentation.

Lenalidomidă Alkaloid-Int belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often combined with dexamethasone or other agents to achieve synergistic effects. While proteasome inhibitors target protein degradation pathways, lenalidomide modulates the immune environment and angiogenesis, providing an alternative or complementary option depending on disease characteristics and prior therapy.

Lenalidomidă Alkaloid-Int should be stored at temperatures below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use. These conditions help maintain the drug’s stability and potency throughout its shelf life.

Lenalidomidă Alkaloid-Int is administered orally, typically as a tablet or capsule taken with water. The exact dosing schedule—such as daily or on specific days of a treatment cycle—is determined by the prescribing physician based on the patient’s condition, response, and tolerance. Patients should follow the healthcare provider’s instructions and not alter the regimen without medical advice.

The most serious risks include thromboembolic events (deep‑vein thrombosis or pulmonary embolism), severe neutropenia or leukopenia that can lead to life‑threatening infections, and rare but severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt medical attention is required if symptoms such as unexplained swelling, fever, severe skin rash, or signs of infection develop.

Lenalidomidă Alkaloid-Int should be avoided in patients with known hypersensitivity to lenalidomide or any of its excipients, in pregnant women, and in individuals with uncontrolled active infections or severe renal impairment without dose adjustment. Additionally, patients taking certain contraindicated medications, such as strong CYP3A4 inducers, should not use this product unless a suitable alternative regimen is selected by the clinician.